The efficiency of triflurigine for reccurence of colorectal liver metastasis.

Phase2 multicenter study of triflurigine for reccurence of colorectal liver metastasis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031220052

Enrollment

Registered

2022-05-10

Start date

2022-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastasis of colorectal cancer Colorectal cancer, Liver metastasis

Interventions

Operation, Trifluridine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrence after resection of liver metastasis of colorectal cancer

Exclusion criteria

Exclusion criteria: Unresectable extrahepatic metastasis

Design outcomes

Primary

Measure	Time frame
Progression free survival at 2 years	—

Secondary

Measure	Time frame
Overall survival at 2 years, Adverse events, Completion rate, Dose intensity, objective response rate, Recurrent type, R0 resection rate, Clavien-Dindo grade IIIa or higher complications	—

Contacts

Public ContactRyota Ito

Juntendo University Hospital

r.ito.nh@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026